Early test of new drug for rare blood disorder
NCT ID NCT04269551
Summary
This small, early-stage study tested a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare autoimmune blood disorder. The main goal was to check the drug's safety and how well it was tolerated. Researchers also measured how the drug affected the body's immune system and the breakdown of red blood cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HAEMOLYTIC ANAEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2760001
Essen, 45147, Germany
-
Investigational Site Number :3800001
Milan, Milano, 20122, Italy
-
Investigational Site Number :5280001
Amsterdam, 1105AZ, Netherlands
-
Investigational Site Number :5780001
Bergen, 5021, Norway
-
Investigational Site Number :8260001
London, London, City of, NW1 2PJ, United Kingdom
-
Investigational Site Number :8400002
Fayetteville, Georgia, 30214, United States
-
Investigational Site Number :8400004
Seattle, Washington, 98108, United States
-
Investigational Site Number :8400006
The Bronx, New York, 10467, United States
-
Investigational Site Number :8400008
Pittsburgh, Pennsylvania, 15232, United States
-
Investigational Site Number :8400009
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.